Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
EFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a potential candidate for ER+ breast cancer trials.
Shares of eFFECTOR Therapeutics, Inc. (EFTR) slipped over 80% on Thursday morning after the company said it would end the development of its tomivosertib non-small cell lung cancer treatment after phase 2 data showed no positive results.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer expected in early April 2024 Median progression free survival of.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024